Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2025-12-25 @ 8:05 PM
Study NCT ID:
NCT07279935
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-12
First Post:
2025-12-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-01-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2030-05-18
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-05-18
Completion Date Type:
ESTIMATED
First Submit Date:
2025-12-01
First Submit QC Date:
None
Study First Post Date:
2025-12-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-01
Last Update Post Date:
2025-12-12
Last Update Post Date Type:
ESTIMATED